FR2838348A1 - Use of alkoxylated polyol fatty acid esters in cosmetic compositions as agents for inhibiting adhesion of microorganisms to the surface of the skin and/or mucosa - Google Patents

Abstract

Esters (I) of alkoxylated polyols and (un)saturated fatty acids having 8-24 carbon atoms are used in cosmetic compositions as agents for inhibiting adhesion of microorganisms to the surface of the skin and/or mucosa. An Independent claim is also included for cosmetic treatment of disorders associated with adhesion of microorganisms by applying a (I)-containing composition to the skin and/or mucosa.

Description

<Desc / Clms Page number 1>

The invention relates to the use of oxyalkylenated polyol esters and fatty acids, in a cosmetic composition or for the preparation of a dermatological composition as an agent preventing or reducing the adhesion of microorganisms on the surface of the skin and / or mucous membranes.

Human skin is permanently populated by a multitude of different microorganisms (bacteria, yeasts and fungi). Commensal microorganisms living on or in the skin may be part of a microflora that is either resident (normal) or transient. The resident microbial flora, essential for good skin health, consists mainly of staphylococci (Staphylococcus epidermis and Staphylococcus hominis), corynebacteria, Gram + propionibacteria such as Propionibacterium acnes, and a fungal flora mainly composed of Pytosporum ovale. . Their presence is established in well-defined distribution profiles. Usually, transient microorganisms do not bind firmly; they are unable to multiply and normally die after a few hours.

The anatomy and physiology of the skin varies from one part of the body to another and the resident microflora reflects these variations.

Most skin bacteria are present on the superficial squamous epidemic, colonizing dead cells and closely associated with the sebaceous and sweat glands. Excretions from these glands provide water, amino acids, urea, electrolytes and specific fatty acids as nutrients primarily for Staphylococcus epidermidis and aerobic corynebacteria.

 Skin infections are most often due to the breakdown of the ecological balance of the resident flora following the colonization of the skin by exogenous pathogens or the abnormal proliferation of an endogenous strain. The most well-known pathogens are Pseudomonas aeruginosa (Gram -) which causes small pimples, folliculitis, redness and pruritus, Candida albicans can cause inflammation at the corner of the lips, cutaneous candidiasis, pruritus, folliculitis and canker sores, Staphylococcus aureus that can cause pimples, folliculitis, impetigo, and boils, and Streptococcus group A responsible for impetigo.

<Desc / Clms Page number 2>

To combat these microorganisms, it is common to use antibiotics or bactericides. The use of these compounds, however, raises the problem of the non-specificity of action aimed indifferently at the pathogenic flora and the resident flora, the problem of the risk of occurrence of bacterial resistance, as well as skin tolerance problems (irritations, allergies, ...).

It is also known to reduce or prevent the colonization of surfaces such as teeth, skin and / or mucous membranes by pathogenic germs by preventing their attachment to these supports. The compounds used as anti-adhesion agents described in the prior art are either silicones (WO-99/62475) or hydrocarbon compounds such as mineral oils or waxes described in the patent application WO-99 / 62475, carbohydrates and carbohydrate derivatives, such as those described in the patent application WO-96/23479.

Most carbohydrates are a source of carbon for bacteria and fungi. Their presence in cosmetic compositions therefore promotes microbial proliferation and requires the increase in the concentration of preservatives (bactericidal or bacteriostatic). This disadvantage thus cancels the benefit of the approach of replacing antibiotic or bactericidal compounds with compounds reducing microbial adhesion.

 The applicant has demonstrated that, surprisingly, esters known for their surfactant properties, significantly reduce the adhesion of microorganisms to the surface of the skin and / or mucous membranes, and thus prevent the proliferation of potentially pathogenic germs in the absence of antibiotic, bactericidal or fungicidal agents, and without the need to use a significant amount of preservatives.

 These esters, unlike the carbohydrates that bind to the receptors of microorganisms to prevent glycolipid binding of corneocytes, act on the physicochemical properties of the surface of the skin and / or mucous membranes, these physical properties. -chemicals involving electrodynamic interactions due to Van der Waals forces, Lewis acid-base interactions and electrostatic interactions.

<Desc / Clms Page number 3>

The subject of the invention is therefore the use of at least one oxyalkylene and saturated or unsaturated chain fatty acid ester containing from 8 to 24 carbon atoms, in a cosmetic composition or for the preparation of a composition dermatological, as an agent preventing or reducing the adhesion of microorganisms on the surface of the skin and / or mucous membranes.

The fatty acids constituting the esters according to the invention are identical or different for the same ester, that is to say that they may all have the same carbon number, or have different chain lengths within the same ester. The carbon chain or chains may be saturated or unsaturated, and linear or branched. Preferably, they contain from 10 to 20 carbon atoms.

By oxyalkylene polyol, within the meaning of the invention is meant polyols free of carbohydrate units, and comprising oxyalkylene units and more particularly oxyethylene units and / or oxypropylene. The preferred oxyalkylenated polyols according to the invention are therefore chosen from oxyethylenated polyols and oxypropylene polyols, and more particularly glycerols or glycols.

 By "preventing or reducing the adhesion of micro-organisms", it is to be understood that the ester or the composition containing it can be used both as a preventive measure, for its ability to prevent, totally or partially, the adhesion of micro-organisms. -organisms, as a cure for its ability to facilitate the detachment of microorganisms.

 An advantageous aspect of the invention relates to the use of at least one ester chosen from oxyalkylenated glycol and saturated or unsaturated chain fatty acid esters containing from 8 to 24 carbon atoms. Polyethylene glycol and fatty acid esters, or polypropylene glycol and fatty acid esters, are more particularly preferred.

<Desc / Clms Page number 4>

As polyethylene glycol ester of fatty acid, mention may in particular be made of polyethylene glycol (8 EO) isostearate, marketed in particular under the reference PRISORINE 364 by the company ICI UNIQEMA.

Another advantageous aspect of the invention relates to the use of at least one ester chosen from oxyalkylene and saturated or unsaturated chain fatty acid esters containing from 8 to 24 carbon atoms. Polyoxyethylene and fatty acid glycerol esters, or polyoxypropylene and fatty acid glycerol esters, are more particularly preferred.

As polyoxyethylenated fatty acid ester of glycerol, mention may in particular be made of polyoxyethylenated (20 EO) glycerol triisostearate, marketed in particular under the reference EMALEX GWIS-320 EX by the company NIHON EMULSION.

In the compositions used in the context of the present invention, the esters of oxyalkylenated polyols and of saturated or unsaturated chain fatty acids containing from 8 to 24 carbon atoms are preferably present in an amount ranging from 0.1% to 30%. % by weight relative to the total weight of the composition, and more particularly in an amount ranging from 0.5% to 20% by weight relative to the total weight of the composition.

 The use of at least one oxyalkylene and fatty acid polyol ester according to the invention finds an application more specifically in the cosmetic or dermatological field. In particular, the compositions containing these esters may be used for cleaning and / or care of the skin, as a sun product, as a make-up product such as foundations, lipsticks, mascaras, blushes, and / or as a simple deodorant.

 More particularly, the invention relates to the use of at least one polyol ester as defined above, as an agent preventing or reducing the adhesion of microorganisms on the surface of the skin and / or mucous membranes in a composition. make-up remover of the skin.

<Desc / Clms Page number 5>

Thus another object of the present invention relates to a cosmetic treatment method for treating disorders related to the adhesion of micoorganismes comprising the application on the skin and / or the mucous membranes of a composition comprising at least one oxyalkylenated polyol ester and saturated or unsaturated chain fatty acid having 8 to 24 carbon atoms in a cosmetically acceptable medium.

The adhesion of microorganisms on the skin and / or mucous membranes has consequences that range from simple inconvenience (odor, pimples, ...) to more serious diseases.

Another aspect of the invention is therefore to propose the cosmetic use of at least one oxyalkylenated polyol ester and saturated or unsaturated chain fatty acid ester comprising from 8 to 24 carbon atoms, as an agent intended for to reduce bad odors, and / or intended for personal hygiene care.

"For personal hygiene care" means a substance intended to be placed in contact with the various superficial parts of the human body and / or with the mucous membranes, and / or with the teeth, for the purpose of cleaning them, protect them, keep them in good condition, change their appearance, perfume them, or correct their odor.

Since the microbial flora on the surface of the skin is responsible for a large number of disorders, the present invention also relates to the use of at least one oxyalkylenated polyol ester and saturated or unsaturated chain fatty acid ester comprising 8 to 24 carbon atoms, in a cosmetic composition or for the preparation of a dermatological composition as an agent against mycoses and / or acne, particularly juvenile acne.

 The compositions used according to the invention are intended for topical application to the skin and / or superficial body growths and therefore contain a physiologically acceptable medium, that is to say, compatible with cutaneous tissues such as the skin, the scalp, eyelashes, eyebrows, hair, nails and / or mucous membranes. This physiologically acceptable medium may more particularly consist of water and optionally of a physiologically acceptable organic solvent chosen for example from among the alcohols

<Desc / Clms Page number 6>

 lowerers having from 1 to 8 carbon atoms and in particular from 1 to 6 carbon atoms, such as ethanol, isopropanol, propanol, butanol; polyethylene glycols having from 6 to 80 ethylene oxide units, polyols such as propylene glycol, isoprene glycol, butylene glycol, glycerin, sorbitol.

The compositions according to the invention may be in any of the galenical forms conventionally used for topical application and especially in the form of aqueous, hydroalcoholic, oily solutions, oil-in-water (O / W) or water-in-water emulsions. oil (W / O) or multiple (triple: W / O / W or O / W / H), aqueous gels, or dispersions of a fatty phase in an aqueous phase using spherules, these spherules may be polymeric nanoparticles such as nanospheres and nanocapsules, or lipid vesicles of ionic and / or nonionic type (liposomes, niosomes, oleosomes). These compositions are prepared according to the usual methods.

In addition, the compositions used according to the invention may be more or less fluid and have the appearance of a white or colored cream, an ointment, a milk, a lotion, a serum, a paste, a foam or a biphase. They may optionally be applied to the skin in the form of an aerosol. They may also be in solid form, for example in the form of a stick.

When the composition used according to the invention comprises an oily phase, it preferably contains at least one oil. It may also contain other fatty substances.

As oils that can be used in the composition of the invention, mention may be made, for example, of: hydrocarbon-based oils of animal origin, such as perhydrosqualene; hydrocarbon-based oils of vegetable origin, such as liquid triglycerides of fatty acids containing from 4 to 10 carbon atoms, for instance triglycerides of heptanoic or octanoic acids or, for example, sunflower, corn or soybean oils, squash, grape seed, sesame, hazelnut, apricot, macadamia, arara, sunflower, castor oil, avocado, triglycerides of caprylic / capric acids such as those sold by Stearineries Dubois or those

<Desc / Clms Page number 7>

 sold under the names Miglyol 810,812 and 818 by Dynamit Nobel, jojoba oil, shea butter oil; esters and synthetic ethers, in particular of fatty acids, such as the oils of formulas R 1 COOR 2 and R 1 OR 2 in which R 1 represents the residue of a fatty acid comprising from 8 to 29 carbon atoms, and R 2 represents a hydrocarbon-based chain, branched or unbranched, containing from 3 to 30 carbon atoms, such as, for example, purcellin oil, isononyl isononanoate, isopropyl myristate, 2-ethylhexyl palmitate, octyl stearate, octyl-2-dodecyl stearate, octyl-2-dodecyl erucate, isostearyl isostearate; hydroxylated esters such as isostearyl lactate, octyl hydroxystearate, octyldodecyl hydroxystearate, diisostearyl malate, triisocetyl citrate, heptanoates, octanoates, decanoates of fatty alcohols; polyol esters, such as propylene glycol dioctanoate, neopentyl glycol diheptanoate and diethylene glycol diisononanoate; pentaerythritol esters such as pentaerythrityl tetraisostearate; linear or branched hydrocarbons of mineral or synthetic origin, such as paraffin oils, volatile or not, and their derivatives, petroleum jelly, polydecenes, hydrogenated polyisobutene such as Parleam oil; fatty alcohols having 8 to 26 carbon atoms, such as cetyl alcohol, stearyl alcohol and their mixture (cetylstearyl alcohol), octyldodecanol, 2-butyloctanol, 2-hexyldecanol, 2-undecylpentadecanol, oleic alcohol or linoleic alcohol; partially fluorinated hydrocarbon oils and / or silicone oils such as those described in document JP-A-2-295912; silicone oils such as volatile or non-volatile polymethylsiloxanes (PDMS) with a linear or cyclic silicone chain, which are liquid or pasty at room temperature, in particular cyclopolydimethylsiloxanes (cyclomethicones) such as cyclohexasiloxane; polydimethylsiloxanes comprising alkyl, alkoxy or phenyl groups, during or at the end of the silicone chain, groups having from 2 to 24 carbon atoms; phenyl silicones such as phenyltrimethicones, phenyldimethicones, phenyltrimethylsiloxydiphenylsiloxanes, diphenyl-dimethicones, diphenylmethyldiphenyltrisiloxanes, 2-phenylethyltrimethylsiloxysilicates, and polymethylphenylsiloxanes;

<Desc / Clms Page number 8>

 - their mixtures.

By hydrocarbon oil is meant in the list of oils mentioned above, any oil predominantly comprising carbon and hydrogen atoms, and optionally ester, ether, fluoro, carboxylic acid and / or alcohol groups.

The other fatty substances that may be present in the oily phase are, for example, fatty acids containing from 8 to 30 carbon atoms, such as stearic acid, lauric acid, palmitic acid and oleic acid; waxes such as lanolin, beeswax, carnauba or candelilla wax, paraffin waxes, lignite waxes or microcrystalline waxes, ceresin or ozokerite, synthetic waxes such as polyethylene waxes, waxes Fischer-Tropsch; silicone resins such as trifluoromethyl-C 1-4 alkyl dimethicone and trifluoropropyldimethicone; silicone elastomers such as the products sold under the names KSG by the company Shin-Etsu, under the names Trefil, BY29 or EPSX by the company Dow Corning or under the names Gransil by the company Grant Industries.

 These fatty substances may be chosen in a varied manner by those skilled in the art in order to prepare a composition having the desired properties, for example of consistency or texture.

 According to a particular embodiment of the invention, the composition according to the invention is a water-in-oil (W / O) or oil-in-water (O / W) emulsion. The proportion of the oily phase of the emulsion may range from 5 to 80% by weight, and preferably from 5 to 50% by weight relative to the total weight of the composition.

 The emulsions generally contain at least one emulsifier chosen from amphoteric, anionic, cationic or nonionic emulsifiers, used alone or as a mixture, and optionally a co-emulsifier. The emulsifiers are suitably selected according to the emulsion to be obtained (W / O or O / W). The emulsifier and the co-emulsifier are generally present in the composition, in a proportion ranging from

<Desc / Clms Page number 9>

 from 0.3 to 30% by weight, and preferably from 0.5 to 20% by weight relative to the total weight of the composition.

For W / O emulsions, examples of emulsifiers that may be mentioned include dimethicone copolyols such as the mixture of cyclomethicone and dimethicone copolyol, sold under the name DC 5225 C by Dow Corning, and alkyl dimethicone copolyols such as Laurylmethicone copolyol sold under the name "Dow Corning 5200 Formulation Aid" by the company Dow Corning and cetyl dimethicone copolyol sold under the name Abil EM 90R by the company Goldschmidt. It is also possible to use, as surfactant of W / O emulsions, a crosslinked solid elastomeric organopolysiloxane comprising at least one oxyalkylenated group, such as those obtained according to the procedure of Examples 3,4 and 8 of US-A-5,412,004 and examples US-A-5,811,487, especially the product of Example 3 (synthetic example) of US-A-5,412,004. and such as that sold under the reference KSG 21 by Shin Etsu.

Examples of O / W emulsions that may be mentioned as emulsifiers are nonionic emulsifiers such as oxyalkylenated fatty acid and sorbitan esters; oxyalkylenated fatty alcohol ethers (oxyethylenated and / or oxypropylenated); sugar esters such as sucrose stearate; their mixtures.

 In an advantageous aspect of the invention, it is not necessary to add an emulsifier to the composition. Indeed, the polyol esters of saturated or unsaturated chain fatty acid according to the invention make it possible to emulsify the composition.

 In known manner, the cosmetic or dermatological composition of the invention may also contain adjuvants customary in the cosmetic or dermatological field, such as active agents, antioxidants, hydrophilic or lipophilic gelling agents, solvents, perfumes, fillers, UV filters, odor absorbers, dyestuffs, plant extracts, salts. The amounts of these various adjuvants are those conventionally used in the field under consideration, and for example from 0.01 to 20% of the total weight of the composition. These adjuvants, according to their nature,

<Desc / Clms Page number 10>

 may be introduced into the fatty phase, into the aqueous phase and / or into the lipid spherules.

As active agents which can be used in the composition of the invention, mention may be made, for example, of desquamating agents, moisturizing agents, depigmenting or pro-pigmenting agents, anti-glycation agents, NO-synthase inhibitors, inhibitors 5a-reductase inhibitors, lysyl and / or prolyl hydroxylase inhibitors, agents stimulating the synthesis of dermal or epidermal macromolecules and / or preventing. their degradation, the agents stimulating the proliferation of fibroblasts or keratinocytes and / or the differentiation of keratinocytes, the antimicrobial agents acting against acne germs, the muscle-relaxing agents, the tensing agents, the anti-pollution or anti-radical agents , soothing agents, lipolytic active agents or having a favorable activity, direct or indirect, on the reduction of adipose tissue, the agents acting on the microcirculation, and the agents acting on the energetic metabolism of the cells.

As fillers which can be used in the composition of the invention, mention may be made, for example, besides the pigments, the silica powder; talcum; polyamide particles and especially those sold under the name ORGASOL by the company Atochem; polyethylene powders; micro-spheres based on acrylic copolymers, such as those in ethylene glycol dimethacrylate / lauryl methacrylate copolymer sold by the company Dow Corning under the name of
POLYTRAP; expanded powders such as hollow microspheres and in particular the microspheres marketed under the name EXPANCEL by the company
Kemanord Plast or under the name MICROPEARL F 80 ED by the company
Matsumoto; silicone resin microbeads such as those sold under the name Tospearl by the company Toshiba Silicone; fibers such as polyamide fibers (eg, nylon 66); their mixtures. These fillers may be present in amounts ranging from 0 to 20% by weight and preferably from
1 to 10% by weight relative to the total weight of the composition.

<Desc / Clms Page number 11>

 According to a preferred embodiment, the compositions used according to the invention may additionally comprise at least one organic photoprotective agent and / or at least one active inorganic photoprotective agent active in water-soluble UVA and / or UVB (absorbers). or fat-soluble or insoluble in commonly used cosmetic solvents.

The organic photoprotective agents are in particular chosen from anthranilates; cinnamic derivatives; dibenzoylmethane derivatives; salicylic derivatives, camphor derivatives; triazine derivatives such as those described in patent applications US 4367390, EP863145, EP517104, EP570838, EP796851, EP775698, EP878469, EP933376, EP507691, EP507692, EP790243, EP944624; benzophenone derivatives; ss, ss-diphenylacrylate derivatives; benzotriazole derivatives; benzalmalonate derivatives; benzimidazole derivatives; imidazolines; bis-benzoazolyl derivatives as described in patents EP669323 and US 2,463,264; p-aminobenzoic acid derivatives (PABA); methylene bis- (hydroxyphenylbenzotriazole) derivatives as described in US5,237,071, US5,166,355, GB2303549, DE 197 26 184 and EP893119; filter polymers and silicone filters such as those described in particular in the application WO-93/04665; dimers derived from α-alkylstyrene such as those described in the patent application
DE19855649; 4,4-diarylbutadienes as described in applications EP0967200,
DE19746654, DE19755649, EP-A-1008586, EP1133980 and EP133981 and mixtures thereof.

 By way of illustration, as UV-A and / or UV-B active photoprotective agents, the following may be mentioned, under the name INCI: p-aminobenzoic acid derivatives ( PABA), in particular PABA, ethyl PABA, ethyl dihydroxypropyl PABA, octyl Dimethyl PABA (sold in particular under the name ESCALOL 507 by ISP), PABA glyceryl, or PEG-25 PABA (sold under the name UVINUL name P25 by BASF),

<Desc / Clms Page number 12>

salicylic derivatives, in particular homosalate (sold under the name EUSOLEX HMS by RONA / EM INDUSTRIES), octyl salicylate (sold under the name NEO HELIOPAN OS by HAARMANN and REIMER), dipropylene glycol salicylate (sold under the name DIPSAL) by SCHER), or the TEA salicylate (sold under the name NEO HELIOPAN TS by HAARMANN and REIMER), the dibenzoylmethane derivatives, in particular butyl Methoxydibenzoylmethane (sold in particular under the trade name PARSOL 1789 by HOFFMANN LA ROCHE), or the isopropyl Dibenzoylmethane, cinnamic derivatives, in particular octyl methoxycinnamate (sold in particular under the trade name PARSOL MCX by Hoffmann la Roche), isopropyl methoxy cinnamate, isoamyl paramethoxy cinnamate (sold under the trade name NEO HELIOPAN E 1000 by HAARMANN and REIMER), cinoxate, DEA methoxycinnamate, diisopropyl methylcinnamate, or glyceryl ethylhexanoate dimethoxycinnamate, derivatives of ss, ss'-diphenylacrylate, in particular the octoc rylene (sold in particular under the trade name UVINUL N539 by BASF), or etocrylene (sold in particular under the trade name UVINUL N35 by BASF), derivatives of benzophenone, in particular benzophenone-1 (sold under the trade name UVINUL 400 by BASF), benzophenone-2 (sold under the trade name UVINUL D50 by BASF), benzophenone-3 or oxybenzone (sold under the trade name UVINUL M40 by BASF), benzophenone-4 (sold under the trade name UVINUL MS40 by BASF), benzophenone-5, benzophenone-6 (sold under the trade name HELISORB 11 by NORQUAY), benzophenone-8 (sold under the trade name SPECTRA-SORB UV-24 PAR
AMERICAN CYANAMID), benzophenone-9 (sold under the trade name UVINUL DS-49 by BASF), benzophenone-12, or n-hexyl 2- (4-diethylamino-2-hydroxybenzoyl) benzoate,

<Desc / Clms Page number 13>

benzylidenecamphor derivatives, in particular 3-benzylidene camphor (manufactured under the name MEXORYL SD by CHIMEX), 4-methylbenzylidene camphor (sold under the name EUSOLEX 6300 by MERCK), benzylidene camphor Sulfonic Acid (manufactured under the name MEXORYL SL by CHIMEX), camphor benzalkonium methosulfate (manufactured under the name MEXORYL SO by CHIMEX), terephthalylidene dicamphor sulfonic acid (manufactured under the name MEXORYL SX by CHIMEX), or polyacrylamidomethyl benzylidene camphor (manufactured under the name MESORYL SW by CHIMEX), benzimidazole derivatives, in particular phenylbenzimidazole sulfonic acid (sold in particular under the trade name Eusolex 232 by Merck), or disodium phenyl dibenzimidazole tetra-sulphonate (sold under the trade name NEO HELIOPAN AP by HAARMANN and REIMER) , triazine derivatives, especially anisotriazine (sold under the trade name TINOSORB S by CIBA SPECIALTY CHEMICALS), ethylhexyl triazone (sold especially under the trade name UVINUL T150 by BASF), diethylhexyl butamido triazone (sold under the trade name UVASORB HEB by SIGMA
3V), or 2,4,6-tris- (4'amino-benzalmalonate diisobutyl) -s-triazine, benzotriazole derivatives, in particular, drometrizole trisiloxane (sold under the name SILATRIZOLE by RHODIA CHEMISTRY), the methylene bis-benzotriazolyl betramethylbutylphenol (sold in solid form under the trade name MIXXIM
BB / 100 by FAIRMOUNT CHEMICAL or in micronized form in aqueous dispersion under the trade name TINOSORB M by CIBA SPECIALTY
CHEMICALS), anthranilic derivatives, in particular menthyl anthranilate (sold under the trade name NEO HELIOPAN MA by HAARMANN and REIMER), imidazoline derivatives, in particular ethylhexyl dimethoxybenzylidene dioxoimidazoline propionate,

<Desc / Clms Page number 14>

 benzalmalonate derivatives, in particular the benzalmalonate functional polyorganosiloxane (sold under the trade name PARSOL SLX by Hoffmann La Roche), and mixtures thereof.

The more particularly preferred organic photoprotective agents are chosen from ethylhexyl salicylate, ethylhexyl methoxycinnamate, octocrylene, phenylbenzimidazole sulphonic acid, benzophenone-3, benzophenone-4, benzophenone-5, 4-methylbenzylidene camphor, terephthalylidene dicamphor sulphonic acid, disodium phenyl dibenzimidazole tetrasulfonate, 2,4,6-tris- (4'-amino benzalmalonate diisobutyl) -s-triazine, anisotriazine, ethylhexyl triazone, diethylhexyl butamido triazone methylene bis-benzotriazolyl tetramethylbutylphenol, drometrizole trisiloxane, and mixtures thereof.

The inorganic photoprotective agents are chosen from pigments or even nanopigments (average size of the primary particles: between 5 nm and 100 nm, preferably between 10 nm and 50 nm) of coated or uncoated metal oxides, for example nano-sized nanopigments. titanium oxide (amorphous or crystallized in rutile and / or anatase form), iron, zinc, zirconium or cerium which are all UV photoprotective agents well known per se. Conventional coating agents are, moreover, alumina and / or aluminum stearate. Such nanopigments of metal oxides, coated or uncoated, are in particular described in patent applications EP518772 and EP518773.

 The photoprotective agents are generally present in the compositions according to the invention in proportions ranging from 0.1 to 20% by weight relative to the total weight of the composition, and preferably ranging from 0.2 to 15% by weight relative to to the total weight of the composition.

<Desc / Clms Page number 15>

The examples which follow serve to illustrate the invention without, however, being limiting in nature. The compounds are, as the case may be, listed in chemical names or CTFA names (International Cosmetic Ingredient Dictionary and Handbook).

 Example 1: Microbial anti-adhesion test: Protocol: The activity of the esters used according to the invention was demonstrated on reconstructed epidermis.

Before bacterial adhesion, the reconstructed epidermis is brought into contact for 2 hours with 25 mg of the ester to be tested at 37 ° C. Then 1 ml of bacterial suspension of Staphylococcus aureus is added at a concentration of 107 seeds / ml. in Tryptone salt. After incubation for 24 hours at 37 ° C., the bacterial suspension is emptied and five rinses are carried out with 1 ml of sterile distilled water. The reconstructed epidermis detached from its support is then ground using a robot in 18ml of Tryptone salt.

This suspension is diluted in Tryptone salt, seeded with 1 ml of the dilution in 15 ml of Trypticase Soy agar and incubated for 24 hours at 37 ° C. The cells are then counted. adherent and viable.

 This anti-adhesion test makes it possible to evaluate the effectiveness of single molecules or finished products.

Before the anti-adhesion test, the following viability test is carried out:
A bacteria / product mixture to be tested, in the same ratio as in the anti-adhesion test, is contacted for 24 hours at 37 ° C. The count of the seeds is carried out by decimal dilution in Tryptone salt and 100 l rake inoculation. on Trypticase Soy agar. Colony count is performed after 24 hours of incubation at 37 C.

 The viability test carried out prior to the anti-adhesion test makes it possible to rule out any bactericidal component of the molecules or finished products tested and to demonstrate only the anti-adhesion activity.

<Desc / Clms Page number 16>

Results: The results obtained are summarized in the following table:

<Tb>
<tb> Activity <SEP> anti-adhesion
<tb> Material <SEP> first <SEP> tested <SEP> Quantitative <SEP> Results <SEP> Qualitative <SEP> Results
<tb> Triisostearate <SEP> from
<tb> polyoxyethylene <SEP> glyceryl-2.27 <SEP> Excellent
<tb> (20 <SEP> OE) <SEP> (16 <SEP>%)
<tb> Isostearate <SEP> from <SEP> polyethylene
<tb> glycol <SEP> (8 <SEP> OE) <SEP> (16 <SEP>%) - 4.01 <SEP> Excellent
<Tb>
The quantitative results correspond to the decimal logarithm decimation of the average number of viable Staphylococcus aureus adherent on the reconstructed epidermis after treatment with the tested ester with respect to the decimal logarithm of the average number of viable Staphylococcus aureus adherent on the reconstructed epidermis after treatment. to water under the same conditions. The results are considered significant if the difference is greater than 0.5 log.

The qualitative results are expressed by a term that varies according to the log reduction values of the adhesion of the germs after 24 hours compared to the same test using water: # results superior to those obtained with water Pro- membership.

 # results identical to those obtained with the water No effect, # between 0. 5 and 1 log of reduction compared to the water Low, # between 1 and 1.5 log of reduction with respect to the water Average, # 1.5 and 2 log reduction compared to good water, # 2 log and more reduction compared to water Excellent,

<Desc / Clms Page number 17>

 EXAMPLE 2 Cleansing Oil: The following composition is produced in a conventional manner for a person skilled in the art, by stirring at room temperature the various constituents, until a perfectly clear medium is obtained.

Isopropyl palmitate 15% Liquid paraffin 20% Polyoxyethylenated glyceryl triisostearate (20 EO) 16% Perfume 0.1% Polyisobutene Hydrogenated qs 100%

Claims (13)

 1. Use of at least one oxyalkylenated polyol ester and saturated or unsaturated chain fatty acid having 8 to 24 carbon atoms, in a cosmetic composition, as an agent preventing or reducing the adhesion of microorganisms on the surface of the skin and / or mucous membranes. 2. Use of at least one oxyalkylenated polyol ester and saturated or unsaturated chain fatty acid having from 8 to 24 carbon atoms, as an agent preventing or reducing the adhesion of microorganisms on the surface of the skin and / or mucous membranes, for the preparation of a dermatological composition. 3. Use according to one of claims 1 or 2, characterized in that the oxyalkylenated polyol is chosen from oxyethylenated polyols and oxypropylene polyols. 4. Use according to one of claims 1 to 3, characterized in that the ester is selected from oxyalkylenated glycol and saturated or unsaturated chain fatty acid esters having 8 to 24 carbon atoms. 5. Use according to claim 4 characterized in that the ester is polyethylene glycol isostearate (80E). 6. Use according to one of claims 1 to 3, characterized in that the ester is selected from oxyalkylenated glycerol esters of saturated or unsaturated chain fatty acid containing from 8 to 24 carbon atoms. 7. Use according to claim 6, characterized in that the ester is polyoxyethylenated (20 EO) glycerol triisostearate. <Desc / Clms Page number 19> 8. Use according to one of claims 1 to 7, characterized in that the ester is present in an amount ranging from 0.1% to 30% by weight relative to the total weight of the composition. 9. Use according to claim 8, characterized in that the ester is present in an amount ranging from 0.5% to 20% by weight relative to the total weight of the composition. 10. Cosmetic treatment process for treating disorders related to the adhesion of micoorganismes comprising the application to the skin and / or the mucous membranes of a composition comprising at least one ester according to one of claims 1 to 7 in a medium cosmetically acceptable. 11. Cosmetic use of at least one ester according to one of claims 1 to 7 as an agent for reducing bad body odor and / or intended for personal hygiene care. 12. Use of at least one ester according to one of claims 1 to 7 for the manufacture of a dermatological composition for combating fungal infections and / or acne. 13. Use of at least one ester according to one of claims 1 to 7, as an agent preventing or reducing the adhesion of microorganisms on the surface of the skin and / or mucous membranes in a makeup removing composition of the skin .